These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19551236)

  • 1. Financial barriers to HIV treatment in Yaoundé, Cameroon: first results of a national cross-sectional survey.
    Boyer S; Marcellin F; Ongolo-Zogo P; Abega SC; Nantchouang R; Spire B; Moatti JP
    Bull World Health Organ; 2009 Apr; 87(4):279-87. PubMed ID: 19551236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of out-of-pocket and catastrophic expenses incurred by patients with Human Immunodeficiency Virus (HIV) in availing free antiretroviral therapy services in India.
    Alvi Y; Faizi N; Khalique N; Ahmad A
    Public Health; 2020 Jun; 183():16-22. PubMed ID: 32413804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financial burden of health care for HIV/AIDS patients in Vietnam.
    Tran BX; Duong AT; Nguyen LT; Hwang J; Nguyen BT; Nguyen QT; Nong VM; Vu PX; Ohinmaa A
    Trop Med Int Health; 2013 Feb; 18(2):212-8. PubMed ID: 23210600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does HIV services decentralization protect against the risk of catastrophic health expenditures?: some lessons from Cameroon.
    Boyer S; Abu-Zaineh M; Blanche J; Loubière S; Bonono RC; Moatti JP; Ventelou B
    Health Serv Res; 2011 Dec; 46(6pt2):2029-56. PubMed ID: 22092226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of antiretroviral therapy (ART) provision in an early cohort of patients initiating ART in Ghana.
    Ohene SA; Addo NA; Zigah F; Newman M; Lartey M; Romero MA; Ofori S; Sheriff T; Ndanu T
    Pan Afr Med J; 2013; 16():117. PubMed ID: 24778754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.
    Dutta A; Barker C; Kallarakal A
    PLoS Med; 2015 Nov; 12(11):e1001907; discussion e1001907. PubMed ID: 26599990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Free care at the point of service delivery: a key component for reaching universal access to HIV/AIDS treatment in developing countries.
    Souteyrand YP; Collard V; Moatti JP; Grubb I; Guerma T
    AIDS; 2008 Jul; 22 Suppl 1():S161-8. PubMed ID: 18664948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of assessing out-of-pocket payments when the financing of antiretroviral therapy is transitioned to domestic funding: findings from Vietnam.
    Johns B; Chau LB; Hanh KH; Huong NT; Do HM; Duong AT; Nguyen LH
    Trop Med Int Health; 2017 Jul; 22(7):908-916. PubMed ID: 28544070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. User fees and access to ARV treatment for persons living with HIV/AIDS: implementation and challenges in Burkina Faso, a limited-resource country.
    Kouanda S; Bocoum FY; Doulougou B; Bila B; Yameogo M; Sanou MJ; Sawadogo M; Sondo B; Msellati P; Desclaux A
    AIDS Care; 2010 Sep; 22(9):1146-52. PubMed ID: 20824567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The macroeconomic consequences of renouncing to universal access to antiretroviral treatment for HIV in Africa: a micro-simulation model.
    Ventelou B; Arrighi Y; Greener R; Lamontagne E; Carrieri P; Moatti JP
    PLoS One; 2012; 7(4):e34101. PubMed ID: 22514619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon (EVAL survey, ANRS 12-116).
    Marcellin F; Boyer S; Protopopescu C; Dia A; Ongolo-Zogo P; Koulla-Shiro S; Abega SC; Abé C; Moatti JP; Spire B; Carrieri MP;
    Trop Med Int Health; 2008 Dec; 13(12):1470-8. PubMed ID: 19000156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decentralization of HIV care in Cameroon: increased access to antiretroviral treatment and associated persistent barriers.
    Loubiere S; Boyer S; Protopopescu C; Bonono CR; Abega SC; Spire B; Moatti JP
    Health Policy; 2009 Oct; 92(2-3):165-73. PubMed ID: 19371960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of switch to paediatric second-line antiretroviral therapy after first-line failure in Cameroon.
    Njom-Nlend AE; Efouba N; Brunelle Sandie A; Fokam J
    Trop Med Int Health; 2021 Aug; 26(8):927-935. PubMed ID: 33905593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-adherence to antiretroviral therapy in Yaounde: prevalence, determinants and the concordance of two screening criteria.
    Pefura-Yone EW; Soh E; Kengne AP; Balkissou AD; Kuaban C
    J Infect Public Health; 2013 Aug; 6(4):307-15. PubMed ID: 23806707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.
    Meresse M; March L; Kouanfack C; Bonono RC; Boyer S; Laborde-Balen G; Aghokeng A; Suzan-Monti M; Delaporte E; Spire B; Carrieri MP; Laurent C;
    HIV Med; 2014 Sep; 15(8):478-87. PubMed ID: 24589279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment interruption in HIV-positive patients followed up in Cameroon's antiretroviral treatment programme: individual and health care supply-related factors (ANRS-12288 EVOLCam survey).
    Tong C; Suzan-Monti M; Sagaon-Teyssier L; Mimi M; Laurent C; Maradan G; Mengue MT; Spire B; Kuaban C; Vidal L; Boyer S;
    Trop Med Int Health; 2018 Mar; 23(3):315-326. PubMed ID: 29327419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to Antiretroviral Therapy (ART) in Yaoundé-Cameroon: Association with Opportunistic Infections, Depression, ART Regimen and Side Effects.
    Fonsah JY; Njamnshi AK; Kouanfack C; Qiu F; Njamnshi DM; Tagny CT; Nchindap E; Kenmogne L; Mbanya D; Heaton R; Kanmogne GD
    PLoS One; 2017; 12(1):e0170893. PubMed ID: 28141867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free access to antiretroviral treatment and protection against the risk of catastrophic health expenditure in people living with HIV: evidence from Cameroon.
    Bousmah MA; Nishimwe ML; Kuaban C; Boyer S
    BMC Health Serv Res; 2021 Apr; 21(1):313. PubMed ID: 33827564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustaining the community dispensation strategy of HIV antiretroviral through community participation.
    Kameni BS; Nansseu JR; Tatah SA; Bigna JJ
    Infect Dis Poverty; 2019 Jan; 8(1):5. PubMed ID: 30674354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: Individual and healthcare supply-related factors.
    Boyer S; Clerc I; Bonono CR; Marcellin F; Bilé PC; Ventelou B
    Soc Sci Med; 2011 Apr; 72(8):1383-92. PubMed ID: 21470734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.